Article
RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.
Cancer cytopathology - 1 Apr 2022
Gilani Syed M, Abi-Raad Rita, Garritano James, Cai Guoping, Prasad Manju L, Adeniran Adebowale J
Abstract excerpt
BACKGROUND: Activating point mutations of the RAS gene (NRAS, HRAS, and KRAS) can be seen in benign and malignant thyroid tumors; among these, NRAS mutations are more commonly seen. This study was conducted to evaluate the thyroid risk of malignancy (ROM) associated with RAS mutations in thyroid fine-needle aspiration (FNA) at the authors' institution. METHODS: The authors searched their electronic database...
Topics
Join the communities discussing this publication.